-
1
Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Gepubliceerd in 2025Andere auteurs: -
2
Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Gepubliceerd in 2025Andere auteurs: -
3
Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Gepubliceerd in 2025Andere auteurs: -
4
Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Gepubliceerd in 2025Andere auteurs: -
5
Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Gepubliceerd in 2025Andere auteurs: “…Alison M. Meynert (14956260)…”
-
6
Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Gepubliceerd in 2025Andere auteurs: “…Alison M. Meynert (14956260)…”
-
7
Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Gepubliceerd in 2025Andere auteurs: “…Alison M. Meynert (14956260)…”
-
8
Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Gepubliceerd in 2025Andere auteurs: “…Alison M. Meynert (14956260)…”
-
9
Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Gepubliceerd in 2025Andere auteurs: “…Alison M. Meynert (14956260)…”
-
10
Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Gepubliceerd in 2025Andere auteurs: “…Alison M. Meynert (14956260)…”